Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00248092 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Likeability, Safety, and Abuse Potential of NRP 104 in Adults With Histories of Stimulant Abuse
A Phase 1 study of Substance-Related Disorders and Attention Deficit Disorder With Hyperactivity, sponsored by New River Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT00248092 is a Phase 1 study of Substance-Related Disorders and Attention Deficit Disorder With Hyperactivity that has completed, run by New River Pharmaceuticals. The registered enrollment target is 36 participants, below the 1,521-participant average among 58 other Substance-Related Disorders trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00248092, a Phase 1 study of Substance-Related Disorders and Attention Deficit Disorder With Hyperactivity, has completed, sponsored by New River Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
This research is being done to evaluate if NRP104 is a safe drug. The other purpose is to learn if NRP104 produces a high and any other effects like amphetamine and other stimulant drugs that are abused. This information will give some indication if NRP104 can be abused. NRP104 is an investigational drug. This means that it has not been approved by the U.S. Food and Drug Administration (FDA). Healthy people, between the ages of 18 and 55 with histories of substance abuse that include stimulant drugs, may join. Amphetamines are drugs that are used most often to treat attention deficit hyperactivity disorder (ADHD) in children, to treat narcolepsy (excessive sleepiness) and for weight loss.
Conditions Studied
Interventions
- DRUG NRP104
Study Locations (1)
Maryland
- Johns Hopkins Bayview Medical Center, Clinical Studies Program - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2006-01 |
| Est. Completion | 2006-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00248092
The ClinicalTrials.gov registry entry for NCT00248092 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,521-participant average among 58 other Substance-Related Disorders trials with a reported enrollment target (98% lower). The listed sponsor is New River Pharmaceuticals, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Substance-Related Disorders appearing as the primary indexed condition, and to 1 intervention - of which NRP104 is the first listed.
NCT00248092 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00248092 about?
NCT00248092 is a clinical study titled "Study to Evaluate the Likeability, Safety, and Abuse Potential of NRP 104 in Adults With Histories of Stimulant Abuse". This research is being done to evaluate if NRP104 is a safe drug. The other purpose is to learn if NRP104 produces a high and any other effects like amphetamine and other stimulant drugs that are abused. This information will give some indication if NRP104 can be abused. NRP104 is an investigational...
What is the current status of trial NCT00248092?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2006-01. Estimated completion is 2006-05.
What conditions does trial NCT00248092 study?
This clinical trial studies the following conditions: Substance-Related Disorders, Attention Deficit Disorder With Hyperactivity, Amphetamine-Related Disorders.
What interventions are being tested in trial NCT00248092?
The interventions under investigation include: NRP104 (DRUG).
Who is sponsoring clinical trial NCT00248092?
This trial is sponsored by New River Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00248092 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Substance-Related Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use Disorder
ACTIVE NOT RECRUITING · Phase 1
-
Pilot Clinical Trial of Computer-based Motivational Intervention - 1
COMPLETED · Phase 1
-
Cognitive Therapy for PTSD in Addiction Treatment
COMPLETED · Phase 1
-
Prepulse Inhibition of Startle in Cocaine Dependence - 7
COMPLETED · Phase 1
-
Evaluation of Lofexidine for Treatment of Opioid Withdrawal - 7
COMPLETED · Phase 1
-
Phase II: Scalable Digital Delivery of CRAFT Training for Professionals to Maximize Treatment Rates of OUD in Families
RECRUITING · NA
Explore more on PlainTrial
Substance-Related Disorders
All registered trials for this condition
Attention Deficit Disorder With Hyperactivity
All registered trials for this condition
Maryland
All trials with a study site in Maryland
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.